Newer parameters of the octreotide test in patients with acromegaly
Authors' conclusion
The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.
Study context
- Population
- Consecutive treatment-naïve patients with acromegaly, April 2008–March 2023
- Participants
- 45 patients
- Exposure
- Newer octreotide test parameters (growth hormone (GH) suppression rate-time AUC, time to nadir GH) vs maximum GH suppression rate for predicting fg-SRL effect
- Outcome
- Therapeutic effects of long-acting first-generation somatostatin receptor ligands (fg-SRLs) (IGF-I reduction, tumor shrinkage) predicted by newer octreotide test parameters (AUC, time to nadir GH) vs maximum GH suppression rate
- Follow-up
- 3 months
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
Prediction of fg-SRL therapeutic effect by octreotide test parameters
- The AUC estimated reductions in serum IGF-I and tumor shrinkage
- Time to nadir GH predicted tumor shrinkage more robustly than maximum GH suppression rate in macroadenoma
Observational data: associations, not effects.
Original publication
Newer parameters of the octreotide test in patients with acromegaly. Pituitary. Published 24 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →